Although numerous compounds targeting CTLA-4 and PD-L1 (programmed death-ligand 1) have been tested in clinical trials for GBM, none have significantly improved survival outcomes for newly diagnosed or recurrent cases in the past decade [14]. This evidence concerns the gene CD274 and glioblastoma.